Compass Therapeutics reported that the FDA recommended it conduct another trial before submitting a regulatory package for tovecimig in previously treated biliary tract cancer. The feedback triggered a sharp share price reaction, highlighting how quickly the FDA can alter development timelines for bispecific antibody programs even after earlier clinical activity.